Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response
A. Cottignies-Calamarte, F. Marteau, F. He, S. Belouzard, J. Dubuisson, D. Tudor, B. Viollet, M. Bomsel
This paper shows that MK-8722, a direct AMPK activator, inhibits SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy, and enhancing type I IFN response, even when applied post-exposure.
bioRxiv · Feb 29, 2024Immunology